منابع مشابه
DPP4 in Diabetes
Dipeptidyl-peptidase 4 (DPP4) is a glycoprotein of 110 kDa, which is ubiquitously expressed on the surface of a variety of cells. This exopeptidase selectively cleaves N-terminal dipeptides from a variety of substrates, including cytokines, growth factors, neuropeptides, and the incretin hormones. Expression of DPP4 is substantially dysregulated in a variety of disease states including inflamma...
متن کاملPolyarthropathy in type 2 diabetes patients treated with DPP4 inhibitors.
Dipeptidyl peptidase-4 inhibitors (DPP-4Is) inhibit the inactivation of incretin hormones while also affecting the immune system, since CD26/DPP-4 is involved in immune regulation. The current study shows that the use of DPP-4Is as therapy for type 2 diabetes patients may induce joint symptoms with decrease in plasma SDF-1α level.
متن کاملTreatments for Type 2 Diabetes; a Focus on DPP4 Inhibitors
New treatments for diabetes are always exciting in the beginning but as experience grows their position in management becomes less certain. This review focuses on DPP4 inhibitors and their place in management of type 2 diabetes. Although hypoglycaemia is rarely an issue, the effectiveness in reduction in blood sugar is greatest at the higher blood sugar levels, hence much of the value of using ...
متن کاملKLK5 induces shedding of DPP4 from circulatory Th17 cells in type 2 diabetes
OBJECTIVE Increasing plasma levels and activity of dipeptidyl peptidase-4 (DPP4 or CD26) are associated with rapid progression of metabolic syndrome to overt type 2 diabetes mellitus (T2DM). While DPP4 inhibitors are increasingly used as anti-hyperglycemic agents, the reason for the increase in plasma DPP4 activity in T2DM patients remains elusive. METHODS We looked into the source of plasma ...
متن کاملDPP4 inhibition prevents AKI
With great interest we have read the publication “Dipeptidyl peptidase 4 inhibitor use is associated with a lower risk of incident acute kidney injury in patients with diabetes” by Chao et al., demonstrating for the first time in a large scale prospectively designed cohort study that the use of DPP-4 inhibitors is associated with a significant risk reduction for the development of acute kidney ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Frontiers in Immunology
سال: 2015
ISSN: 1664-3224
DOI: 10.3389/fimmu.2015.00386